世界の糖尿病性足部潰瘍治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Related Reports 16
2.3 Upcoming Related Reports 16
3 Disease Overview 17
3.1 Etiology and Pathophysiology 17
3.1.1 Etiology 17
3.1.2 Pathophysiology 18
3.2 Assessment of DFUs 19
3.2.1 Patient History and Visual Examination 20
3.2.2 Testing for Neuropathy 20
3.2.3 Testing Vascular Status 20
3.2.4 Identifying Infection 21
3.3 Classification of Diabetic Foot Ulcers 21
3.4 Prognosis 23
4 Epidemiology 24
4.1 Disease Background 24
4.2 Risk Factors and Comorbidities 24
4.2.1 An increased duration of diabetes triples the risk of DFUs 25
4.2.2 Men diabetics are at higher risk for DFUs than women diabetics 26
4.3 Global Trends 26
4.3.1 US 27
4.3.2 5EU 28
4.4 Forecast Methodology 29
4.4.1 Sources Used 30
4.4.2 Sources Not Used 32
4.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes 33
4.4.4 Forecast Assumptions and Methods, Diabetic Foot Ulcers 36
4.5 Epidemiological Forecast for DFUs (2012-2022) 40
4.5.1 Total Prevalent Cases of DFUs 40
4.5.2 Age-Specific Total Prevalent Cases of DFUs 42
4.5.3 Sex-Specific Total Prevalent Cases of DFUs 44
4.5.4 Total Prevalent Cases of Diabetic Foot Infections 45
4.6 Discussion 47
4.6.1 Epidemiological Forecast Insight 47
4.6.2 Limitations of the Analysis 47
4.6.3 Strengths of the Analysis 48
5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles – Wound-Healing Agents 53
5.2.1 Regranex (becaplermin) Gel 53
5.3 Product Profiles – Cell-Based Skin Substitutes 60
5.3.1 Dermagraft (human fibroblast-derived dermal substitute) 60
5.3.2 Apligraf (bi-layered skin substitute) 65
5.3.3 Grafix (human cellular repair matrix) 69
6 Unmet Needs Assessment and Opportunity Analysis 73
6.1 Overview 73
6.2 Unmet Needs Analysis 74
6.2.1 Improved Patient and Physician Education: Emphasis on the Importance of Off-Loading 74
6.2.2 Improved Multidisciplinary Approach to Patient Treatment with Common Protocols 76
6.2.3 More Effective Treatments for Neuroischemic Wounds 78
6.2.4 More Effective Antibacterial Treatments for Infected DFUs 79
6.2.5 Affordable Products and Improved Reimbursement 79
6.2.6 In-Home Sensing Systems for the Early Prevention of DFUs 81
6.3 Opportunity Analysis 82
6.3.1 Wound-Healing Agents for the Treatment of Neuroischemic Ulcers 82
6.3.2 Topical Antibiotics for the Treatment of DFUs 82
6.3.3 Enzymatic Debriding Agents 84
7 Research and Development Strategies 85
7.1 Overview 85
7.1.1 Local Administration of Growth Factors and Bioactive Peptides 85
7.1.2 Cellular Therapies: Leukocytes, Platelets, and Stem Cells 86
7.1.3 Acquisitions and Licensing Agreements Between Wound Care Companies 87
7.2 Clinical Trial Design 89
7.2.1 Current Clinical Trial Design 89
7.2.2 Standardization of Debridement and Off-Loading 91
7.2.3 Inclusion of Representative Patient Populations in Clinical Trials 93
8 Pipeline Assessment 95
8.1 Overview 95
8.2 Promising Wound-Healing Agents in Clinical Development 96
8.2.1 CureXcell (activated leukocyte suspension) 96
8.2.2 DSC127 (NorLeu3-angiotensin[1-7]) 102
8.2.3 Trafermin (recombinant human basic fibroblast growth factor spray) 107
8.2.4 CVBT-141B (topical human fibroblast growth factor-1) 112
8.3 Promising Antimicrobial Agents in Clinical Development 113
8.3.1 Cogenzia (gentamicin-collagen sponge) 113
8.3.2 Locilex (pexiganan acetate cream) 119
8.4 Innovative Early-Stage Approaches 124
9 Pipeline Valuation Analysis 127
9.1 Clinical Benchmark of Key Pipeline Drugs 128
9.2 Commercial Benchmark of Key Pipeline Drugs 129
9.3 Competitive Assessment 130
9.4 Top-Line Five-Year Forecast 134
9.4.1 US 136
9.4.2 5EU 137
10 Appendix 139
10.1 Bibliography 139
10.2 Abbreviations 150
10.3 Methodology 153
10.4 Forecast Methodology 153
10.4.1 Percent Diagnosed Patients 154
10.4.2 Percent Drug-Treated Patients 154
10.4.3 Drugs Included in Each Therapeutic Class 154
10.4.4 Launch Dates 155
10.4.5 General Pricing Assumptions 155
10.4.6 Individual Drug Assumptions 156
10.5 Physicians and Specialists Included in This Study 160
10.6 About the Authors 161
10.6.1 Analyst, Cardiovascular and Metabolic Disorders 161
10.6.2 Senior Epidemiologist 161
10.6.3 Therapy Director – CVMD and Infectious Disease 162
10.6.4 Global Head of Healthcare 162
10.7 About GlobalData 163
10.8 Disclaimer 163